ClinicalTrials.gg
RecruitingNCT06527391Updated Aug 5, 2026

Choline and Iron Deficiency

A Phase 2/3 interventional study of choline bitartrate and placebo drug in Pediatric Iron Deficiency and Anemia, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 5 Months to 7 Months. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by University of Minnesota · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Phase
Phase 2/3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
5 Months to 7 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 464 studies in Anemia with a site in United States — 38 open to participants now, 59 under way, 19 of them phase 3. Anemia · United States.

Planned enrollment
83rd of 395
300 · median 72
Started
2025
with 9 others
Phase 2/3
8 of 464
1 open now
Primary completion
2027-09
later than 30 of 57 live
Registered
441st of 464
by date

Among the 464 studies in Anemia with a site in United States, this one is the 83rd largest by planned enrollment of the 395 interventional ones that give a count, is one of 10 that started in 2025, is one of 8 in phase 2/3, reaches primary completion later than 30 of the 57 other live ones, and was the 441st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

This study's planned enrollment of 300 is above the median of 117 across 1,336 interventional studies indexed under Anemia.

Browse Anemia studies →

Open to participants now

38 of the 464 studies in Anemia with a site in United States are open now.

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 5 Months to 7 Months · all sexes · no healthy volunteers.

The full table on the hub →
Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 464 studies in Anemia with a site in United States, or all of them as a file.
02

Study summary

BACKGROUND:

Iron deficiency limits the neurodevelopmental potential of more than 200 million children each year. Iron therapy is typically started when iron deficiency anemia is first diagnosed after screening for anemia or detection of clinical symptoms of iron deficiency anemia at 12 months of age. But iron started at this time does not fully correct earlier iron-deficiency-mediated brain dysfunction, underscoring the need for low-cost, easily implementable adjunct therapies to iron to treat or prevent this dysfunction in high-risk populations.

GAP Supplementation with the nutrient choline lessens damage to the hippocampus from early-life iron deficiency in pre-clinical models and improves hippocampus-mediated memory in children with Fetal Alcohol Spectrum Disorders. Choline has not been tested in children with iron deficiency anemia, despite strong pre-clinical and clinical evidence supporting a benefit to brain development.

HYPOTHESIS:

Infants with iron deficiency anemia who receive iron and nine months of daily choline supplements will have better scores on specific neurobehavioral tests of recognition memory than infants who receive iron and placebo.

METHODS:

This randomized, double-blinded, placebo-controlled clinical trial will randomize 300 6-month-old infants with iron deficiency anemia at Mulago Hospital, Kampala, Uganda, to iron plus choline or iron plus placebo to test the effect of choline on hippocampus-specific and global neurobehavioral outcomes after nine months.

RESULTS: Pending

IMPACT:

If our hypothesis is correct, choline could be added immediately to standard-of-care treatment for iron deficiency anemia. This intervention could safely mitigate the brain dysfunction of early-life iron deficiency that is often undiagnosed until the hippocampal critical window is closing. This simple, low-cost nutrient could thus have life-long benefit for both individuals and the economic and social prosperity of entire regions.

03

Conditions studied

  • Pediatric Iron Deficiency
  • Anemia

Keywords

  • iron deficiency
  • choline
  • anemia
04

Who can participate

Ages eligible
5 Months to 7 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 months +/- 28 days
  • \< 11.0 g/dL
  • ZPP > = 80
  • T\<37.5°C
  • Malaria-negative based on Rapid Diagnostic Test (RDT)
  • Mother is -negative.

Exclusion criteria

Exclusion Criteria:

  • Developmental disorder
  • Severe malnutrition (severe wasting or bipedal edema)
  • Known sickle cell disease
  • Neurologic disorder, brain injury, or other condition affecting brain development
  • Not currently breastfeeding
  • Birthweight \< 2000 g
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    study group

    participants assigned to receive study drug

    Drug: choline bitartrate

  • Placebo comparator
    control group

    participants assigned to receive placebo drug

    Other: placebo drug

Interventions

  • Daily supplementation for 9 months with 200 mg choline bitartrate

  • Otherplacebo drug

    Daily supplementation for 9 months with identical placebo

06

What researchers measure

Primary outcomes

  1. Elicited Imitation score

    Elicited Imitation outcomes (number of items correctly recalled and number of steps recalled in the correct order for both immediate and delayed recall) at age 15 months, i.e., after nine months of daily supplementation with choline or placebo.

    Time frame: 9 months (1 month = 28 days) after enrollment

  2. 1) Composite Score on the Mullen Scales of Early Learning; 2) Behavior Rating Scale (BRS) composite score; 3) Early Childhood Vigilance Test (ECVT, computerized test for attention).

    1\) Composite Score on the Mullen Scales of Early Learning; 2) Behavior Rating Scale (BRS) composite score; 3) Early Childhood Vigilance Test (ECVT, computerized test for attention).

    Time frame: 9 months (1 month = 28 days) after enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cusick SE, Mupere E, Bangirana P, Baluku RI, Kroupina M, Cheatham CL, Wozniak JR, Georgieff MK. Supplemental choline to prevent and treat learning and memory deficits of early-life iron deficiency (The SupCHO Study): study protocol for a randomized, placebo-controlled trial in Ugandan infants with iron deficiency anemia. Trials. 2025 Nov 19;26(1):524. doi: 10.1186/s13063-025-09246-2. PubMed 41257751 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 30, 2024
StartActual
Aug 11, 2025
Primary completionEst.
Sep 21, 2027
CompletionEst.
Sep 21, 2027
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527391
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Aug 11, 2025
Primary completion
Sep 21, 2027 (estimated)
Completion
Sep 21, 2027 (estimated)
Last update
Aug 5, 2026

Study contacts

Sarah Cusick
Contact
scusick@umn.edu
612-723-1694
Sarah Cusick
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Choline

Start the discussion